© 2002 by Annals of the Rheumatic Diseases
REPORT
Adalimumab (a fully human anti-tumour necrosis factor
monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials
Department of Rheumatology, Evangelisches Fachkrankenhaus Ratingen, Ratingen, Germany
Correspondence to:
Correspondence to:
Dr R Rau, Rheumaklinik, Evangelisches Fachkrankenhaus, Rosenstr 2 D-40882 Ratingen, Germany;
rrau@uni-duesseldorf.de
Keywords: rheumatoid arthritis; adalimumab
Abbreviations: RA, rheumatoid arthritis; TNF
, tumour necrosis factor
; MTX, methotrexate; DMARD, disease modifying antirheumatic drug
| The first 150 words of the full text of this article appear below. |
Rheumatoid arthritis (RA), a common, chronic, idiopathic autoimmune disease, is characterised by symmetrical synovitis, inflammatory exudates in the joint cavity, and erosion of articular cartilage and marginal bone.1 Standard treatment for RA typically consists of traditional disease modifying antirheumatic drugs (DMARDs), corticosteroids, non-steroidal anti-inflammatory drugs, and analgesics.2 Despite these various treatments, many patients with RA continue to experience substantial disease activity, with progressive joint damage and accompanying functional loss. In recent years, insights into the pathophysiology of RA have lead to the development of novel therapeutic strategies that target underlying disease processes, the most promising of which entails neutralisation of tumour necrosis factor
(TNF
).3
TREATMENTS
TNF
is a potent proinflammatory cytokine that plays a critical part in the progression of inflammatory synovitis and articular matrix degradation in RA.3 Increased concentrations of TNF
are found in the synovial fluid and serum of patients with active RA.4 Derived primarily from activated monocytes
This article has been cited by other articles:
-
Biester, S., Deuter, C., Michels, H., Haefner, R., Kuemmerle-Deschner, J., Doycheva, D., Zierhut, M.
(2007). Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol
91: 319-324
[Abstract] [Full Text] -
Fredericks, Z. L., Forte, C., Capuano, I. V., Zhou, H., Vanden Bos, T., Carter, P.
(2004). Identification of potent human anti-IL-1RI antagonist antibodies. Protein Eng Des Sel
17: 95-106
[Abstract] [Full Text] -
Hochberg, M C, Tracy, J K, Hawkins-Holt, M, Flores, R H
(2003). Comparison of the efficacy of the tumour necrosis factor {alpha} blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis
62: ii13-16
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
